The annual report of the European Medicines Agency (EMA) for 2019 has been released, giving insights into the work done by the Agency during the year.
The EMA reports numerous statistics showing its performance and how many interactions have been made with the industry. It reports:
“In 2019, the CAT [Committee for Advanced Therapies] received 70 requests for ATMP [advanced therapy medicinal product] classification (27% more than in 2018) and adopted 67 recommendations, an increase of 56% compared to 2018.
“One ATMP, Zynteglo, was recommended for marketing authorisation by the CHMP in 2019. Zynteglo is intended for the treatment of transfusion-dependent β-thalassaemia.”
More detail is provided on other successes and work from the year, including Brexit:
“EMA, the European Commission and the Member States continued to work closely together to provide guidance to help companies marketing human and veterinary medicines in the EU to prepare for the UK’s withdrawal from the EU and minimise the impact on the supply of medicines.”
Find the report here, including a new digital version for easier navigation.